Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults

ClinicalTrials.gov ID: NCT07885956

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07885956. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A SECOND DOSE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE GIVEN 5 YEARS AFTER THE INITIAL DOSE IN OLDER ADULTS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.

Study identification

NCT ID
NCT07885956
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
750 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 29, 2026 (Estimated)
Primary completion
Feb 7, 2029 (Estimated)
Completion
Feb 7, 2029 (Estimated)
Last update posted
Nov 20, 2026

2026 – 2029

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Fiel Family and Sports Medicine/Avacare Clinical Research Network Tempe Arizona 85283 —
West Coast Research Dublin California 94568 —
Universal Axon Clinical Research Doral Florida 33166 —
Rovia - Palmetto Bay Miami Florida 33176 —
DBC Research USA Pembroke Pines Florida 33029 —
Javara Inc Albany Georgia 31707 —
Solaris Clinical Research Meridian Idaho 83646 —
Summit Headlands LLC Portland Oregon 97210 —
Accellacare US Inc., d/b/a Accellacare of Knoxville Knoxville Tennessee 37912 —
DM Clinical Research-Tomball Tomball Texas 77375 —
J. Lewis Research Inc. / Foothill Family Clinic Draper Draper Utah 84020 —
J. Lewis Research, Inc/Jordan River Family Medicine South Jordan Utah 84095 —
Sound Health Care Center Port Orchard Washington 98366 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07885956, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2026 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.